View in EDS HTML Full Text PDF Full Text

Understanding CYP3A4 and P-gp mediated drug-drug interactions through PBPK modeling - Case example of pralsetinib.

Saved in:
Bibliographic Details
Title: Understanding CYP3A4 and P-gp mediated drug-drug interactions through PBPK modeling - Case example of pralsetinib.
Authors: Bowman C; Genentech, Inc., South San Francisco, California, USA., Dolton M; Genentech, Inc., South San Francisco, California, USA., Ma F; Genentech, Inc., South San Francisco, California, USA., Cheeti S; Genentech, Inc., South San Francisco, California, USA., Kuruvilla D; Genentech, Inc., South San Francisco, California, USA., Sane R; Genentech, Inc., South San Francisco, California, USA., Kassir N; Genentech, Inc., South San Francisco, California, USA., Chen Y; Genentech, Inc., South San Francisco, California, USA.
Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Apr; Vol. 13 (4), pp. 660-672. Date of Electronic Publication: 2024 Mar 13.
Publication Type: Journal Article
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2163-8306 (Electronic) Linking ISSN: 21638306 NLM ISO Abbreviation: CPT Pharmacometrics Syst Pharmacol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38481038
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Understanding CYP3A4 and P-gp mediated drug-drug interactions through PBPK modeling - Case example of pralsetinib.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Bowman+C%22">Bowman C</searchLink>; Genentech, Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Dolton+M%22">Dolton M</searchLink>; Genentech, Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Ma+F%22">Ma F</searchLink>; Genentech, Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Cheeti+S%22">Cheeti S</searchLink>; Genentech, Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Kuruvilla+D%22">Kuruvilla D</searchLink>; Genentech, Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Sane+R%22">Sane R</searchLink>; Genentech, Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Kassir+N%22">Kassir N</searchLink>; Genentech, Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Chen+Y%22">Chen Y</searchLink>; Genentech, Inc., South San Francisco, California, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101580011%22">CPT: pharmacometrics & systems pharmacology</searchLink> [CPT Pharmacometrics Syst Pharmacol] 2024 Apr; Vol. 13 (4), pp. 660-672. <i>Date of Electronic Publication: </i>2024 Mar 13.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101580011 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2163-8306 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221638306%22">21638306 </searchLink><i>NLM ISO Abbreviation: </i>CPT Pharmacometrics Syst Pharmacol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38481038
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/psp4.13114
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 660
    Titles:
      – TitleFull: Understanding CYP3A4 and P-gp mediated drug-drug interactions through PBPK modeling - Case example of pralsetinib.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Bowman C
      – PersonEntity:
          Name:
            NameFull: Dolton M
      – PersonEntity:
          Name:
            NameFull: Ma F
      – PersonEntity:
          Name:
            NameFull: Cheeti S
      – PersonEntity:
          Name:
            NameFull: Kuruvilla D
      – PersonEntity:
          Name:
            NameFull: Sane R
      – PersonEntity:
          Name:
            NameFull: Kassir N
      – PersonEntity:
          Name:
            NameFull: Chen Y
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: 2024 Apr
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 2163-8306
          Numbering:
            – Type: volume
              Value: 13
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: CPT: pharmacometrics & systems pharmacology
              Type: main
ResultId 1